In this latest study, the Vaxart oral H1N1 influenza vaccine induced anti-hemagglutinin antibody responses in 88 percent of subjects. Four-fold increases in neutralizing antibodies as determined by hemagglutination inhibition assay (HAI) and microneutralization (MN) assay were detected in 45 and 55 percent of subjects, respectively.
"These results demonstrate that the Vaxart oral vaccine can protect against flu and represent a significant milestone on our way to the world's first oral seasonal flu vaccine," said Vaxart CEO
In its next step toward developing a complete oral quadrivalent seasonal influenza vaccine, Vaxart plans to conduct further clinical studies in 2014 with its tablet vaccines for H1N1 influenza A, H3N2 influenza A and influenza B.
"The success of public vaccination programs depends to a large extent on logistics, and each year the annual flu vaccination campaign puts the system to the test," said Vaxart chief medical officer
Vaxart's H1N1 influenza vaccine candidate has demonstrated an excellent safety profile in all studies to date, with no vaccine-related significant adverse events. Adverse events that did occur were all mild.
Vaxart produces its influenza vaccine tablets utilizing industry-standard cell-culture and solid-dose manufacturing processes, which enable manufacturing and distribution of the annually updated vaccine to the public considerably faster than egg-based influenza vaccine manufacturing technologies. About Vaxart Vaxart is a privately owned company developing oral recombinant vaccines based on its proprietary delivery platform. The Vaxart platform is suitable to deliver any protein vaccine antigen such as those used in currently marketed influenza, hepatitis B and human papilloma virus (HPV) blockbuster vaccines.
Keywords for this news article include: Vaxart, Therapy, Vaccination, Flu Vaccines, Immunization, Viral Vaccines, Influenza Vaccines, Biological Products, Adverse Drug Reaction.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- India Recognizes Transgender People as 'Third Gender'
- German Firm Starts Gas Deliveries to Ukraine
- Alfonso Wins Executive of the Year Award
- Five Secrets for Keeping a Job
- The 420 on the Hemp Products Giveaway
- Study: Casual Marijuana Use May Cause Brain Changes
- Bankrupt Detroit Makes Deal With Retired Cops, Firefighters
- Coca-Cola Soda Sales Lose Pop
- Grand Jury Seated in Rick Perry Ethics Case
- U.S. Homebuilder Confidence Edged Up in April